LIP AS A MARKER OF IMMUNOPROTECTION IN SIV

LIP 作为 SIV 免疫保护的标志

• 批准号: 2646526
• 负责人: Darryl L. Carter
• 金额: $ 10.8万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2646526
• 关键词: Macaca nemestrina; T cell receptor; alveolar macrophages; cellular immunity; comorbidity; cytokine; cytotoxic T lymphocyte; immunoregulation; interstitial lung diseases; lymphocytosis; natural killer cells; pathologic process; prognosis; simian AIDSs; simian immunodeficiency virus; virus load

DESCRIPTION (Adapted from applicant's abstract) Lymphoid interstitial pneumonitis (LIP) and diffuse infiltrative lymphocytosis syndrome (DILS) are HIV-related disorders associated with improved survival. An important feature which these two conditions share in common is marked infiltration of the lungs by CD8+t lymphocytes. A condition similar to LIP and DILS occurs in a substantial fraction of macaques experimentally inoculated with certain strains of simian immunodeficiency virus (SIV). Macaques with this condition also have an improved survival time. It is proposed to employ the SIV/macaque model of LIP/DILS to test the hypothesis that the pulmonary cell-mediated immune response in these conditions provide systemic immunologic benefit and retard disease progression. (End of Abstract)

描述 （改编自申请人摘要）假性间质性肺炎（LIP） 和弥漫性浸润性淋巴细胞增多综合征（DILS）与艾滋病毒有关 与提高生存率相关的疾病。 一个重要的特征， 这两种情况的共同点是， CD 8 +T淋巴细胞。 类似于LIP和DILS的情况发生在 实验性接种了某些 猴免疫缺陷病毒（SIV）。 猕猴用这个 条件也有改善的生存时间。 建议采用 LIP/DILS的SIV/猕猴模型，以检验肺动脉高压的假设。 这些病症中的细胞介导的免疫应答提供了系统性的 免疫益处和延缓疾病进展。 (End摘要）